Submitted a provisional patent for TREGingTM
Exclusive license (TREGableTM) from the NIAID, NIH
Opened a BSL2 laboratory for R&D
Exclusive licenses (FVIII TCR and BAR) from the Henry M. Jackson Foundation and Uniformed Services University
INTERACT meeting with US FDA to prepare the IND application of FVIII TCR-Treg in Hemophilia A
Converted the company structure to C-corporation, now TeraImmune, Inc.
Awarded Production Assistance for the Cellular Therapies (PACT), NHLBI, NIH
Awarded Small Business Innovation Research (SBIR) phase I grant, NHLBI, NIH
Foundation of TeraImmune, LLC.